KymaThera secures $80 million in Series B financing led by Alta Partners to advance its K-1728 inhibitor for cancer treatment. This round includes participation from Venrock, Foresite Capital, and J. Wood Capital.
PRIVATEOct 06, 2026
Amount Raised
$80 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeutics
Investors
J. Wood CapitalForesite CapitalVenrockAlta Partners
Description
KymaThera has announced the closing of an $80 million Series B financing round. The funding will support the advancement of K-1728, a pan-mutant selective PI3Kα inhibitor. This financing follows a successful Series A round and aims to initiate Phase 1 patient dosing in late 2026. The funds will primarily be used for the development of treatments for breast cancer and vascular malformations.
Company Information
Company
KymaThera
Location
San Diego, California, United States
About
KymaThera is a biotechnology company developing next-generation precision medicines for genetically defined diseases. It focuses on creating targeted therapies to address substantial unmet needs in conditions such as cancer and vascular malformations. The company's lead product, K-1728, is an investigational oral pan-mutant selective PI3Kα inhibitor aimed at addressing the limitations of existing treatments. With the goal of advancing innovative treatments, KymaThera's approach emphasizes rigorous scientific methods and experienced leadership.
Fundz sees it the moment KymaThera raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealth CareTherapeutics